Directory · LV
Biotechnology in Latvia
A register of firms and the professionals working at them in the Biotechnology sector based in Latvia. Browse the public index, then filter or export on Kipplo.
Companies
6 on file
Mgi Latvia
Latvia MGI Tech (MGI Latvia) is a subsidiary of MGI Tech Co, Ltd.(MGI), a global leader in life science innovation, established in 2016 and now operating in more than 50 countries and regions serving more than customers worldwide. MGI is is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare. MGI’s multi-omics platforms include reagents, medical imaging, laboratory automation, and genetic sequencing. MGI solutions are used in such sectors as scientific research, agriculture, and healthcare. Recently the company's equipment has been contributing to increasing Covid-19 testing capabilities in multiple countries around the world including Sweden, Denmark, Italy, Spain, Australia, Canada, the United States, South Korea, Thailand, Israel, and beyond since the first Covid-19 outbreak in early 2020. MGI Latvia was established in Riga in late 2019, and acts as a hub of Research and Development, production, logistics and specialised training for MGI’s business development in Europe and other international regions. The square-metre facility has a Global Product Application Demo Centre and a state-of-art Sequencing Centre. MGI Latvia focuses on providing effective real-time, comprehensive, life-long solutions for Europe andand other international regions. MGI Latviahas been the largest foreign investment in the biotechnology sector in Latvia and the Baltics to date, exceeding 15 million euros. MGI Latvia has formed extensive collaborations with local research centres. One of the key collaborators is the Latvian Biomedical Research and Study Center. The company participates in a number of major national projects including ERDF, and Horizon 2020 projects. MGI Latvia is a member of the Foreign Investors' Council in Latvia and the Latvian Chamber of Commerce and Industry.
11 to 50 staff
Happy Fish
Happy Fish's main goal is caring for the environment, and that's why our brilliant minds have created a unique bio-surfactant with a high bio-carbon content (90-95%) and biodegradation within 10 days. While searching for possible applications for our surfactant, we discovered a very specific niche - fat accumulation and regular blockages in the sewage systems of food production and food processing companies. Due to its excellent grease removal properties, our bio-surfactant quickly became a customized solution to grease problems in sewage systems. Our unique base of biosurfactants allows us to create various solutions, and we have focused on developing several niche products. Currently, we are actively operating in the Latvian market, as well as studying the market of the Baltic countries and Europe. The potential for our biosurfactants to develop various niche products is enormous, and the demand for environmentally friendly solutions will continue to rise.
1 to 10 staff
Medrego Gene & Stem Cell Therapy Innovations
Medrego Biotech Innovations & Advisory is your partner in the Life Science world! Our expertise covers CAR T-cell therapies, Gene Therapies, Stem Cell Therapies, and ATMP product development and regulatory frameworks. Medrego team expert experience- acting as a member of the European Medicines Agency (EMA) Committee for Advanced Therapy Products and Cell Product Working Party- professional involvement in the classification and marketing authorization evaluation procedures- participation in the drafting process of related guidelines- Core membership of the Cell Product Working Party (CPWP) at the European Medicines Agency (EMA)- External expertise at The State Agency of Medicines- Taking part in successful EU project R&D activities- Private Business consultations for the European Commission, Government bodies, KPMG, Voisin Consulting and others.
11 to 50 staff
Enzymity
We are developing a method for breaking down polymers such as plastics and resins into monomers with the help of synthetic enzymes. The enzymes are tailored for specific types of material (e.g. PET or synthetic rubber) and are produced by genetically modified microorganisms. The monomers which result from the process can be used to create new virgin polymers, thus reducing the need for fossil fuel derived plastics/resins. The cycle can be repeated many times and does not deteriorate the quality of the material, as opposed to the currently prevalent mechanical recycling.
1 to 10 staff
Cellbox Labs
We are developing organs on a chip that are miniature organ replicas outside human body. We are focusing on microbiome and gut on on chip that allows to develop drugs more effective and study biological processes. We are also developing easy to use instrument to run experiments on the chips.
1 to 10 staff
Sintez Company, Sia
We produce highly digestible allergen-free hemp protein and products from it.
1 to 10 staff
